Fresenius (company)

Line

Fresenius SE & Co. KGaA is a German medical technology and healthcare company based in Bad Homburg. The company is one of the largest private hospital operators in Germany as well as in the pharmaceutical and health services operate. In addition, Fresenius is a majority stake in the dialysis specialist Fresenius Medical Care. Since 23 March 2009, the company is listed on the DAX, the German stock exchange. With effect from 13 July 2007, the German company from a stock corporation (AG) law was transferred into a European Company (SE). On 28 January 2011, the conversion was carried out in a partnership limited by shares ( KGaA).

History

Founded in Frankfurt am Main in 1462 Hirsch-Apotheke arrived in the 18th century in the hands of Fresenius family. The pharmacist and owner of Hirsch-Apotheke, Eduard Fresenius, in 1912 he founded the pharmaceutical company Dr. E. Fresenius. Its main products were pharmaceutical specialties such as injectable solutions, serological reagents and Bormelin nasal ointment. The production company was 1933/34, separated from the Hirsch Pharmacy and relocated to Bad Homburg. The company dealt in the following years about 400 employees. The unexpected death of Eduard Fresenius endangered in 1946, the continued existence of the pharmacy and manufacturing operation. Worked there only 30 employees at this time. Else Kröner, which was still called at that time Else Fernau, took over in 1951 after a study pharmacy with her husband Hans Kröner responsibility for the pharmacy and manufacturing operations and expanded the product line infusion solutions. In 1966, the sales of dialysis machines and dialyzers of various foreign manufacturers and the profit significant market share in this segment was.

The introduction of an amino acid solution after the potato - egg - pattern 1971 Fresenius achieved a substantial contribution to the parenteral nutrition therapy. 1974 began in St. Wendel (Saarland), the production of infusion solutions and medical disposables. Today Fresenius there produces innovative Polysulfone dialyzers. In Schweinfurt, began in 1979 the production of its own dialysis equipment, the A2008.

1981 The company was converted into a public limited company, which went public in 1986. In 1983 began the production of synthetic polysulfone membranes for dialysis, which determine the quality standard to this day. 1996 as part of the acquisition of the U.S. company National Medical Care subsidiary Fresenius Medical Care AG & Co. KGaA ( previously Fresenius Medical Care AG) was founded, which is the world's leading provider of dialysis products and services today.

In 1997 in Friedberg (Hessen) the hitherto most advanced solution for infusion factory in Europe in operation. A year later, Fresenius took over the international infusion business of Pharmacia & Upjohn. By merging with the Fresenius Fresenius Kabi Pharmaceuticals business sector, Europe's leading company emerged in the field of nutrition and infusion therapy. In the same year the new corporate headquarters in Bad Homburg was purchased.

In 2001, Fresenius AG with the Wittgenstein clinics around 30 acute and specialist clinics and 4,600 employees. 2005, the acquisition of Helios Kliniken followed for 1.5 billion euros.

With the takeover of the U.S. Renal Care Group, 2006, Fresenius strengthened its leading position in the field of dialysis. In world more than 2,700 dialysis clinics around 210,000 patients are cared for (as of December 2010).

In 2008, Fresenius increased by the acquisition of US-based APP Pharmaceuticals in the North American pharmaceutical market and became one of the world's leading provider of intravenously administered generic drugs.

Fresenius AG moved to approval of an extraordinary general meeting on December 4, 2006 - with effect from 13 July 2007 - the legal form into a European Company and changed its name since then as Fresenius SE. On 28 January 2011, the Group announced the change of legal form of Fresenius SE into a partnership limited by shares ( KGaA ) is known in connection with the conversion of preference shares into ordinary shares.

2012 Fresenius planned to take over the hospital group Rhön -Klinikum and merge with Helios to a group that did not succeed.

On September 13, 2013, the Company announced that it has entered with the Rhön- Klinikum AG a contract for the acquisition of 43 hospitals and 15 medical care centers.

Group structure

Companies in the Group:

  • Fresenius Medical Care AG & Co. KGaA: Worldwide leading provider of products and services for patients with chronic kidney failure, currently listed in the DAX.
  • Fresenius Helios: Helios Kliniken GmbH: more than 18,500 beds in 63 hospitals (as of February 2011) In 2001, Fresenius Wittgensteiner Kliniken AG with 30 acute care and specialty hospitals and 4,600 staff
  • In 2005, Fresenius Helios GmbH, about 9,345 beds (2004), about 1.157 billion euros turnover ( 2004), 17,600 employees (2004)
  • January 1, 2006: the Wittgenstein Kliniken AG is fused with the HelioS
  • Hospitalia international: global consulting, service and engineering services for turnkey new construction, renovation, equipping and maintenance of hospitals, clinics, rehabilitation and health care facilities
  • Vamed AG: consulting, design, construction and equipping of hospitals, health resorts, senior centers and spa facilities, management of health facilities, project developments, especially for devices in health tourism ( participation to 77 percent)

Not for the Group comprises the Institute Fresenius and Fresenius University. In June 2013, Fresenius also announced the sale of the existing biotechnology business, Fresenius Biotech to the Israeli entrepreneur family Fuhrer known.

Shareholder

As of February 3, 2011

Types of business entity International Securities Identification Number Profit (economics) Friedberg, Hesse Blood transfusion SGL Carbon The Linde Group Adidas Bayer Continental AG Deutsche Post Deutsche Telekom E.ON Siemens Altana Dresdner Bank Epcos Karstadt Mannesmann Salzgitter AG VEBA
351710
de